MarketCap
Facebook
X
TelegramAzurRx BioPharma, Inc. General and Administrative Expenses 2011-2025 | AZRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AzurRx BioPharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 7.29 M | 6.06 M | 8.24 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.24 M | 6.06 M | 7.2 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.93 | 4.78 % | $ 818 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
22.2 M | $ 3.2 | -1.69 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
10.2 M | $ 1.07 | -5.75 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 213.33 | -3.22 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.13 | -4.96 % | $ 7.53 B |  Australia |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
8.57 M | $ 1.42 | -1.85 % | $ 2.1 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
286 M | $ 93.93 | -0.93 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 26.45 | 4.67 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 9.6 | 0.37 % | $ 141 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.26 | -6.98 % | $ 566 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
14.7 M | $ 12.98 | -7.91 % | $ 854 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
741 M | $ 548.58 | -2.78 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.37 | 2.83 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
15.2 B | $ 91.59 | 1.95 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
38.5 M | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.97 | -0.44 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 11.33 | -1.78 % | $ 733 M | USA |
 |
Biogen
BIIB
|
2.4 B | $ 175.2 | 0.63 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
19 M | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
280 M | $ 87.67 | -0.36 % | $ 9.05 B | USA |
 |
ADiTx Therapeutics
ADTX
|
16.3 M | $ 1.43 | -36.18 % | $ 18.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
11.7 M | $ 3.28 | -9.39 % | $ 40.1 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
59 M | $ 24.29 | 2.84 % | $ 2.88 B | USA |